Celselect Slides 2.0

Bio-Rad Launches Celselect Slides 2.0 to Advance Rare Cell and Circulating Tumor Cell Enrichment for Cancer Research

“CTCs are rare — as low as only 1–10 can be found per milliliter of blood — however, CTC enumeration and analysis offers valuable insight into tumor heterogeneity and disease progression,” said Stephen Kulisch, Vice President of Marketing for Bio-Rad’s Digital Biology Group. “Building on the capabilities of Celselect Slides 1.0, we’re continuing to improve the efficiency of rare CTC enrichment, enumeration, and recovery to accelerate cancer research workflows. This launch reflects the expansion of our technological capabilities and our commitment to bringing novel solutions to researchers to improve our understanding of cancer and inform research programs.”